Improving Racial and Ethnic Minority Representation in Cardiovascular Disease Trials to Advance Health Equity-Reply

JAMA Cardiol. 2020 May 1;5(5):611-612. doi: 10.1001/jamacardio.2020.0146.

Authors

Robert T Sparrow^{1

2}, Laura E Ferreira-Legere², Jacob A Udell^{2

3

4

5}

Affiliations

¹ Faculty of Medical Science, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada.
² ICES, Toronto, Ontario, Canada.
³ Department of Medicine, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
⁴ Peter Munk Cardiac Centre, University Health Network, Toronto, Ontario, Canada.
⁵ Cardiovascular Division, Women's College Hospital, Toronto, Ontario, Canada.

PMID: 32129798
DOI: 10.1001/jamacardio.2020.0146

No abstract available

Publication types

Letter
Comment

MeSH terms

Cardiovascular Diseases* / therapy
Ethnicity
Health Equity*
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors*
Minority Groups
Randomized Controlled Trials as Topic

Substances

Hydroxymethylglutaryl-CoA Reductase Inhibitors